Indications for: EXEM FOAM
For sonohysterosalpingography to assess fallopian tube patency in women with known or suspected infertility.
See full labeling. Give by slow intrauterine infusion using a 5-Fr or larger catheter with luer connection. Initially 2–3mL, may be repeated in increments of 2–3mL as needed to achieve visualization. Max total dose: 10mL.
EXEM FOAM Contraindications:
Pregnancy. Known or suspected lower genital tract inflammation or infections (eg, pelvic inflammatory disease, suspected sexually transmitted disease). Gynecologic procedure within the last 30 days (eg, curettage, conization). Vaginal bleeding: due to the risk of intravasation of ExEm Foam as a result of exposure of the endometrial vessels during bleeding; and due to the potential risk of endometriosis as a result of seeding the peritoneum with endometrial tissue. Known or suspected reproductive tract neoplasia due to the risk of peritoneal spread of neoplasm.
EXEM FOAM Warnings/Precautions:
Risk for fetal harm. Exclude pregnancy status within 24 hours prior to administration. Confirm patient is in the pre-ovulatory phase of menstrual cycle (cycle days 6–11). Risk for post-procedure gynecological infections. Nursing mothers.
EXEM FOAM Classification:
Pelvic/abdominal pain, vasovagal reactions (nausea, faintness), post-procedure spotting; gynecologic infections.
Generic Drug Availability:
Kit—1 (one syringe of clear gel + one syringe of sterile purified water + one Combifix adaptor)